• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Breye Therapeutics

Monday, June 03, 2024
CP
Ophthalmology
Breye Therapeutics is a clinical stage biopharmaceutical company developing first-in-class small molecule drugs suited for oral administration in patients with vascular eye diseases - Specifically, patients with Diabetic Retinopathy (DR) and Age-related Macular Degeneration (AMD). The focus of the company is to develop orally administered products that are suited for earlier treatment intervention providing more effective and less burdensome treatment options for the very large and growing number of patients with DR and AMD - before they progress to advanced disease stages requiring needle-based therapies that are administered directly into the eye. The company is being lead by a strong team of ophthalmology experts and drug developers with a proven track record of successful product development leading to market entries.
Breye Therapeutics
Company Website: https://breye.com
Lead Product in Development: Danegaptide
Number Of Unlicensed Products (For Which You Are Seeking Partners): 2

Website

https://breye.com

Company HQ City

Hoersholm

Company HQ State

Denmark

Company HQ Country

Denmark

CEO/Top Company Official

Ulrik Mouritzen, MD, eMBA

Lead Product in Development

Danegaptide

Development Phase of Primary Product

Phase I
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS